QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:FENC

Fennec Pharmaceuticals (FENC) Stock Forecast, Price & News

$7.20
-0.15 (-2.04%)
(As of 09/26/2023 ET)
Compare
Today's Range
$7.12
▼
$7.40
50-Day Range
$7.20
▼
$8.91
52-Week Range
$7.02
▼
$10.85
Volume
43,847 shs
Average Volume
96,296 shs
Market Capitalization
$191.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Fennec Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
122.2% Upside
$16.00 Price Target
Short Interest
Bearish
7.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$235,550 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

859th out of 964 stocks

Biological Products, Except Diagnostic Industry

137th out of 159 stocks

See Top Rated MarketRank™ Stocks Here

FENC stock logo

About Fennec Pharmaceuticals (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

FENC Price History

FENC Stock News Headlines

August 10, 2023 | finance.yahoo.com
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2023 Earnings Call Transcript
August 4, 2023 | msn.com
HC Wainwright & Co. Maintains Fennec Pharmaceuticals (FENC) Buy Recommendation
September 26, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
August 4, 2023 | markets.businessinsider.com
Maxim Group Keeps Their Buy Rating on Fennec Pharmaceuticals (FENC)
July 31, 2023 | finance.yahoo.com
Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023
July 14, 2023 | theglobeandmail.com
Instrument Name Fennec Pharmaceuticals Inc Instrument Symbol (FENC-Q)
June 21, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Buy Rating for Fennec Pharmaceuticals (FENC)
June 14, 2023 | finanznachrichten.de
Fennec Pharmaceuticals Inc.: Fennec Announces Results of Annual Meeting
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
June 8, 2023 | finance.yahoo.com
Retail investors who hold 38% of Fennec Pharmaceuticals Inc. (NASDAQ:FENC) gained 13%, institutions profited as well
June 6, 2023 | finance.yahoo.com
Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients
May 17, 2023 | insidermonkey.com
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2023 Earnings Call Transcript
May 12, 2023 | markets.businessinsider.com
Maxim Group Sticks to Its Buy Rating for Fennec Pharmaceuticals (FENC)
May 11, 2023 | finanznachrichten.de
Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023 | msn.com
Recap: Fennec Pharmaceuticals Q1 Earnings
May 11, 2023 | finance.yahoo.com
Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023 | investing.com
Fennec Pharma (FRX) Earnings Dates & Reports
May 10, 2023 | msn.com
Earnings Outlook For Fennec Pharmaceuticals
April 27, 2023 | theglobeandmail.com
Closing Bell: Fennec Pharmaceuticals Inc flat on Wednesday (FRX)
April 26, 2023 | theglobeandmail.com
Closing Bell: Fennec Pharmaceuticals Inc flat on Tuesday (FRX)
April 13, 2023 | bizjournals.com
Cipla seeks to dismiss RTP drugmaker's patent lawsuit
April 7, 2023 | msn.com
Cantor Fitzgerald Maintains Fennec Pharmaceuticals (FENC) Overweight Recommendation
April 6, 2023 | markets.businessinsider.com
Analyst Ratings for Fennec Pharmaceuticals
April 5, 2023 | msn.com
HC Wainwright & Co. Reiterates Fennec Pharmaceuticals (FENC) Buy Recommendation
March 31, 2023 | markets.businessinsider.com
Fennec Receives Positive CHMP Opinion For Pedmarqsi In Pediatric Oncology Patients
March 30, 2023 | finanznachrichten.de
Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results
March 30, 2023 | markets.businessinsider.com
Craig-Hallum Remains a Buy on Fennec Pharmaceuticals (FENC)
See More Headlines
Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FENC Company Calendar

Last Earnings
8/03/2023
Today
9/26/2023
Next Earnings (Estimated)
11/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FENC
CUSIP
N/A
CIK
1211583
Web
www.fennecpharma.com
Phone
919-636-4530
Fax
919-890-0490
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+130.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-23,710,000.00
Net Margins
N/A
Pretax Margin
-528.63%
Return on Equity
-7,266.90%
Return on Assets
-107.25%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.12
Quick Ratio
4.74

Sales & Book Value

Annual Sales
$1.53 million
Price / Sales
126.71
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.10) per share
Price / Book
-72.80

Miscellaneous

Outstanding Shares
26,630,000
Free Float
23,631,000
Market Cap
$193.87 million
Optionable
Optionable
Beta
0.24
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Rostislav Raykov (Age 42)
    Pres, CEO & Director
  • Mr. Robert C. Andrade (Age 43)
    Chief Financial Officer
  • Mr. Mark Gowland
    Controller
  • Mr. Lei Fang
    Pres of Pharstat Inc
  • Ms. Anne McKay (Age 64)
    Regulatory Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













FENC Stock - Frequently Asked Questions

Should I buy or sell Fennec Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FENC shares.
View FENC analyst ratings or view top-rated stocks.

What is Fennec Pharmaceuticals' stock price forecast for 2023?

2 analysts have issued 1-year target prices for Fennec Pharmaceuticals' stock. Their FENC share price forecasts range from $15.00 to $17.00. On average, they predict the company's share price to reach $16.00 in the next year. This suggests a possible upside of 119.8% from the stock's current price.
View analysts price targets for FENC or view top-rated stocks among Wall Street analysts.

How have FENC shares performed in 2023?

Fennec Pharmaceuticals' stock was trading at $9.60 at the start of the year. Since then, FENC stock has decreased by 24.2% and is now trading at $7.28.
View the best growth stocks for 2023 here.

When is Fennec Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 10th 2023.
View our FENC earnings forecast.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) announced its earnings results on Thursday, August, 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.03. The firm had revenue of $3.33 million for the quarter, compared to analyst estimates of $4.01 million.

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Who are Fennec Pharmaceuticals' major shareholders?

Fennec Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include DG Capital Management LLC (4.04%), BlackRock Inc. (3.12%), Gendell Jeffrey L (1.07%), State Street Corp (0.98%), Geode Capital Management LLC (0.74%) and Northern Trust Corp (0.43%). Insiders that own company stock include Chris A Rallis, Robert Andrade and Rosty Raykov.
View institutional ownership trends.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fennec Pharmaceuticals' stock price today?

One share of FENC stock can currently be purchased for approximately $7.28.

How much money does Fennec Pharmaceuticals make?

Fennec Pharmaceuticals (NASDAQ:FENC) has a market capitalization of $193.87 million and generates $1.53 million in revenue each year. The company earns $-23,710,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The official website for the company is www.fennecpharma.com. The company can be reached via phone at 919-636-4530 or via fax at 919-890-0490.

This page (NASDAQ:FENC) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -